StreetAlpha.app
Home › Stocks › PYXS

Pyxis Oncology, Inc. (PYXS)

$1.81
▲ +7.74%
LAST CLOSE · NOV 20

Pyxis Oncology develops experimental cancer drugs, led by an antibody drug conjugate for head and neck squamous cell carcinoma. It last closed at $1.81 on Nov 20, up 7.74% on the day. The next earnings report for PYXS is expected around Mon, Mar 22, 2027. For the quarter ended Sep 2026, PYXS reported EPS of -$0.24. Over its last 8 reports the stock moved an average of 7.0% the session after earnings. Over the last 12 months PYXS insiders bought $0 of stock on the open market and sold $107K, according to SEC Form 4 filings.

AI Auto Pilots
Is PYXS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold PYXS.

Key Stats

Last 12 months
Results
Net income
−$86.7M
EPS (diluted)
−$1.27
Free cash flow
−$70.9M
Valuation
Market cap
$216.5M
119.6M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$3.9M
At Sep 30
Shareholder equity
$41.3M
Shares outstanding
119.6M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $16.1M$16.1MFY2024FY2025: $13.9M$13.9MFY2025

From PYXS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Mar 22
Estimated date · Time not announced
Reported EPS
-$0.24
Quarter ended Sep 2026
Year ago EPS
-$0.35
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.59Dec '24Mar 2025: -$0.35Mar '25Jun 2025: -$0.30Jun '25Sep 2025: -$0.35Sep '25Dec 2025: -$0.29Dec '25Mar 2026: -$0.37Mar '26Jun 2026: -$0.40Jun '26Sep 2026: -$0.24Sep '26Latest -$0.24
Revenue by quarter
Dec 2024: $0Dec '24Jun 2025: $2.8MJun '25Sep 2025: $0Sep '25Dec 2025: $11.0MDec '25Latest $11.0M
How PYXS moved after its last 8 reports
Average move the session after a report ±7.0%
Nov 5, 2026Time not announced−3.0%
Aug 13, 2026Time not announced−5.3%
May 14, 2026Time not announced−15.7%
Mar 23, 2026Time not announced−3.4%
Nov 3, 2025Time not announced+7.0%
Aug 14, 2025After the close+8.8%
May 15, 2025Time not announced+3.7%
Mar 18, 2025Time not announced−8.6%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on PYXSStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on PYXS: 0 upgrades, 0 downgrades, 0 initiations
HC WainwrightReiterated
Nov 20  

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on PYXS
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on PYXS

Technical Analysis

PYXS · as of the Nov 20 close · updated each morning
Downtrend

The stock sits between its 20 and 50 day averages. It is 19% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 52). The nearest support is the Pivot S1 at $1.68, and the nearest resistance the Pivot at $1.83.

Short trendBearish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityNormal, 9.6%/day
Key levels
$5.5552 week high+206.6%
$2.57100 day average+42.0%
$2.16200 day average+19.3%
$2.1350 day average+17.7%
$1.97Pivot R1+8.8%
$1.87Swing high (Jun 5)+3.3%
$1.83Pivot+1.1%
$1.81Last close
$1.68Pivot S1−7.2%
$1.6720 day average−7.7%
$1.66Swing low (Oct 16)−8.3%
$1.0352 week low−43.1%
Indicators
RSI (14)51.91Middle of its rangeNeutral
MACD-0.13Above its signal lineBullish
Stochastic50.2Middle of its rangeNeutral
ADX (14)35.8Trending up
Williams %R-27.7Oversold below −80, overbought above −20Neutral
CCI (20)100.9Oversold below −100, overbought above 100Overbought
Rate of change+9.0%Change over 10 sessionsBullish
ATR (14)$0.17Typical daily range, 9.6% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for PYXS

What happened before

See how PYXS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow PYXS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How PYXS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for PYXSHow many large options trades hit PYXS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

PYXS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲64 buying vs 32 selling
  • ▲Held by funds +38.2 pts
  • ▲Funds holding +25
  • ▲Superinvestors: 3 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding10176+32.9%
In funds' top 1042+100.0%
Held by funds66.7%28.6%+38.2 pts
New / increased38 / 269 / 24+93.9%
Reduced / sold out19 / 1324 / 10−5.9%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PYXS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

PYXS Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$107K1 sale · 1 insider
100% of the selling was under pre-arranged trading plans.
2026-06 sold $107KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jun 30Jakob DupontDirectorSale plan35,000$3.06$107K
Apr 21, 2025Rachel HumphreyDirectorSale plan15,496$1.02$16K
Nov 26, 2024Pamela Ann ConnealyCFO & COOBuy88,850$1.96$174K
Every insider buy and sale for PYXS over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See PYXS insider trades →

From SEC Form 4 filings by PYXS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PYXS is in one of them and how their past PYXS trades turned out.

PYXS in the AI portfolios
Loading…

PYXS News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PYXS in an article yet. Here's the latest on the wider market.

PYXS in the news

About Pyxis Oncology

Pyxis Oncology is a cancer drug developer based in Boston, Massachusetts. Its lead product candidate, micvotabart pelidotin, is an experimental antibody drug conjugate that targets a protein found in the tissue surrounding tumors rather than on cancer cells themselves. The company is focused on head and neck squamous cell carcinoma and is testing the drug alone and together with Keytruda, an immunotherapy made by Merck. The drug is still in clinical testing and is not approved for sale, and it is aimed at patients with solid tumors.

Headquarters
Boston, MA